BridgeMD
New treatment option for Patient Compliance
Official title Reminder Strategies to Improve Meal-Logging Adherence
ClinicalTrials.gov ID: NCT07555262
What this study is testing
- What it's testing
- This study is a single-center micro-randomized trial, aiming to examine the effects of two theory-driven reminder strategies on adherence to repeated, image-based meal logging in adults age 45 and older. Three times daily, participants are automatically randomized to receive one of three reminder messages prior to each habitual mealtime.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 45 and older. Healthy volunteers may be eligible.
You may be able to join if
- Citizens or residents of Switzerland who are German-speaking (main place of living or employment in Switzerland).
- Age ≥45 years.
- BMI ≥25 kg/m² (overweight or obese).
- Regular access to a smartphone (iOS or Android) with a data plan.
- Able to use smartphone applications.
You likely can't join if
- History of stroke, heart disease, renal failure, cancer, or diabetes (type 1 or type 2).
- Past vascular bypass surgery or angioplasty.
- Current or planned use of glucose-lowering medications during the upcoming 4 weeks (e.g., GLP-1 receptor agonists, metformin).
- Pregnant or breastfeeding.
- Relevant skin conditions at wearable placement sites (e.g., upper arm).
- BMI \<25 kg/m² confirmed at enrollment.
See the full eligibility criteria
- Citizens or residents of Switzerland who are German-speaking (main place of living or employment in Switzerland).
- Age ≥45 years.
- BMI ≥25 kg/m² (overweight or obese).
- Regular access to a smartphone (iOS or Android) with a data plan.
- Able to use smartphone applications.
- Able to walk independently.
- History of stroke, heart disease, renal failure, cancer, or diabetes (type 1 or type 2).
- Past vascular bypass surgery or angioplasty.
- Current or planned use of glucose-lowering medications during the upcoming 4 weeks (e.g., GLP-1 receptor agonists, metformin).
- Pregnant or breastfeeding.
- Relevant skin conditions at wearable placement sites (e.g., upper arm).
- BMI \<25 kg/m² confirmed at enrollment.
- FPG ≥7.0 mmol/L and/or HbA1c ≥6.5% (newly identified type 2 diabetes); Individuals who meet type-2 diabetes criteria at enrollment, based on Swiss/ADA diagnostic criteria will be informed of blood test results and...
The study team makes the final eligibility decision.
Where it's taking place
- Sankt Gallen, Canton of St. Gallen, Switzerland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 45 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Sankt Gallen, Canton of St. Gallen, Switzerland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.